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Background: The origin of 40% of syncope remains unknown even after
a complete diagnostic work-up. Previous studies have suggested that ade-
nosine 5’-triphosphate (ATP) testing has value in selecting successful therapy.
This patient-blinded, multicenter, randomized superiority trial tested whether,
in patients with syncope of unknown origin (SUO), selecting cardiac pacing
in those with a positive ATP test results in fewer recurrences than those who
do not receive pacing.
Methods and Results: From 2000 to 2005, 80 consenting patients (mean
age 75.9±7.7 years; 81% women; 56% without diagnosed structural heart
disease) with syncope of unknown origin and atrioventricular or sinoatrial
block lasting longer than 10 seconds (average 17.9±6.8 seconds) under ATP
administration (20 mg IV bolus) were recruited from 10 hospitals, implanted
with programmable pacemakers and randomized to either active pacing (dual-
chamber pacing at 70 beats per minute (bpm) or backup pacing (atrial pacing
at 30 bpm). Patients were followed regularly for up to five years for any syn-
cope recurrence, the primary outcome.
Mean follow-up was 16 months. Syncope recurred in eight (21%) of
39 patients randomized to active pacing and in 27 (66%) of 41 randomized to
backup pacing (control), yielding a hazard ratio of 0.25 (95% CI: 0.12-0.56).
After recurrence, the 27 recurrent control patients were reprogrammed to
active pacing and only one reported subsequent syncope.
Conclusions: This study suggests that, in elderly patients with syncope of
unknown origin and positive ATP tests, active dual-chamber pacing reduces
syncope recurrence risk by 75% (95% confidence interval, 44-88).
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Background: Extracellular adenosine-5’-triphosphate (ATP) suppresses
cardiac pacemakers' automaticity and AV nodal conduction directly and indi-
rectly by adenosine and a triggered cardio-cardiac vagal reflex. This action
constitutes the rationale for the ATP-test, a diagnostic tools aimed to identify
patients with syncope of unknown origin (SUO) who could benefit from pace-
maker therapy. Two criteria have been used to determine a positive outcome
of the ATP test: (i) the duration of ATP-induced cardiac pause (CP) due to
AV nodal conduction block or suppressed sinus node, ignoring escape beats,
and (ii) the maximal RR interval irrespective of the origin of the QRS com-
plexes (RRmax). The test is deemed positive when CP is >10 sec or RRmax
>6 sec Two contrasting conclusions regarding the utility of the test have been
reached using these two criteria. The aim of the current post-hoc study, was
to explain the discrepancy between the two conclusions.
Methods: ATP test consists on an I.V. bolus injection of 20 mg of ATP
into an antecubital vein. We analyzed data of 33 patients-cohort derived from
a multicenter study having incorporated 80 SUO patients (Circulation
2012;125:31-6), in which the ATP-test was positive using the CP duration and
negative using the RRmax interval. The 47 remaining patients had both tests
positive and were excluded from this analysis.
Results: A dual chamber pacemaker was implanted in all 33 patients: in
14 and 19 patients the pacemaker was programmed for DDD70 bpm and
AAI30 bpm (control) pacing modes, respectively. Syncope recurred in only
one of the 14 DDD70 patients (7%) during a follow up period of 17.0±8.6
months, but in 10 of the 19 AAI30 patients (53%) during 5.3±5.2 months
(p<0.009).
Conclusion: This study shows that ATP-test is a useful diagnostic tool for
identifying patients with bradycardic syncope who might benefit from pacing
therapy when the CP criterion -and not the RRmax criterion- is used to deter-
mine the outcome of the test.
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Non valvular atrial fibrillation (NVAF) is associated with an increased risk
of stroke. CHADS2 score is used to guide thromboporphylaxis among patients
with NVAF. Copeptine a vasoactive peptide reflecting cardiac stress has been
recently evaluated in combination with Troponin to exclude the diagnosis of
acute coronary syndrome but had never been tested in atrial fibrillation. We
evaluated the relation between the CHADS2 score and several biomarkers
representing multiple pathways implicated in non valvular atrial fibrillation.
Methods: Plasma concentrations of Troponin I (TnI), BNP, mid-regional
proatrial natriuretic peptide (MR-proANP)), hs- CRP, D-dimer and mid-
copeptin (CT-proAVP)) were measured at the time of admission in 45 NVAF
consecutive patients. The association between the median values of these
markers, clinical characteristics, transthoracic echocardiographic parameters
and stroke risk stratification as assessed by the CHADS2 score was tested.
Results: Baseline patients characteristics were as follows: mean age was
64.6±14.9 years, 56% were men, 51% had hypertension, and 7% had diabetes. In
seven patients (16%) NVAF was associated with acute heart failure. Thirtheen
patients (29%) had a prior AF. NVAF was paroxysmal in 67% of patients Mean
LV EF was 54.3±15.7%.and mean LA surface was 21.6±7.1 cm².
Mean CHADS score was 1.1±1 
Table 1 depicted the level of each biomarkers according to the CHADS2
score ANP, Copeptine, hs-CRP, D-dimer levels were increased with the
increased of the CHADS2 score.
Conclusion: Copeptine levels were found to be higher in patients at higher
risk of thrombo embolism as assessed by CHADS2 score.
Table 1 – Results
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The management and prognosis of heart diseases (HD) or arrhythmias may
depend on the patient gender. The purpose of the study was to look for the
influence of gender on the indications and the long-term results of ablation of
atrial flutter (AFl).
Methods: 965 patients, 743 males, 222 females (23%), mean age 64±
12 years were consecutively referred for radiofrequency ablation of recurrent
CHADS2=0 CHADS2=1 CHADS2 >= 2
N=15
median (IQR)
n=14
median (IQR)
n=16
median (IQR) 
 
p
BNP (pg/ml) 244 
(96-378)
394.5 
(120-524)
433.5 
(248.5-644)
0,1422
ANP (pmol/l) 108.9 
(86.56-188.9)
257.2
(122.6-391.4)
305.05
(244.75-406.3)
0,0037
Troponin I (ng/ml) 0.04 
(0.04-0.04)
0.04 
(0.04-0.04)
0.04 
(0.04-0.06)
0,4919
Copeptine (pmol/l) 7.39 
(5-9.48)
8.005 
(5-17.21)
13.685 
(9.145-26.845)
0,0221
Hs CRP (mg/l) 3 (1.53-10) 4.085 (1.96-10) 10 (6.53-34.05) 0,0247
D – dimer (ng/ml) 267 (215-366) 682 (250-751) 816 (516-1055) 0,0346
